fenoximone
Small moleculeexperimental
Clinical trial activity
5 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
3
Phase 3
3
Phase 4
2
Earliest trial started Feb 1, 2002 (NCT00051285)
Timeline
2000s
- Jan 1, 2002
Earliest Phase 3 Sponsor(trial)
Indications
Approved for
Mechanism of action
Chemistry & pharmacology
Loading structure…
SMILES
CSc1ccc(C(=O)c2[nH]c(=O)[nH]c2C)cc1- Mol. weight
- 248.31 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL249856 ↗
Also known as
- enoximone
- enoximone
- enoximone
- enoximone
- enoximone
- enoximone
- fenoximone
- fenoximone
- fenoximone
- fenoximone
- fenoximone
- fenoximone
- mdl-17043
- mdl-17043
- perfan
- perfan
- perfan
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04420455 | Phase 4 | Jul 31, 2020 | Rijnstate Hospital |
| NCT00484133 | Phase 4 | Jun 1, 2007 | Onze Lieve Vrouw Hospital |
| NCT00348101 | Phase 3 | Jun 1, 2006 | Aarhus University, University of Heidelberg |
| NCT00077948 | Phase 3 | Jul 1, 2003 | AstraZeneca, Gilead Sciences |
| NCT00051285 | Phase 3 | Feb 1, 2002 | Gilead Sciences |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Gilead Sciences | For profit | 2 | 2 | 1 | 2002 |
| Aarhus University | Academic/Hospital | 1 | 0 | 1 | 2006 |
| AstraZeneca | For profit | 1 | 0 | 1 | 2003 |
| Onze Lieve Vrouw Hospital | Academic/Hospital | 1 | 1 | 1 | 2007 |
| Rijnstate Hospital | Academic/Hospital | 1 | 1 | 1 | 2020 |
| University of Heidelberg | Academic/Hospital | 1 | 1 | 1 | 2006 |
6 organizations
Page 1 / 1